Economic burden of stroke across Europe: A population-based cost analysis, Eur. Stroke J, vol.87319, p.0, 2019. ,
Global, regional, and national burden of stroke, 1990-2016: A systematic analysis for the Global Burden of Disease Study, Lancet Neurol, vol.18, issue.19, pp.30034-30035, 2016. ,
Determining the number of ischemic strokes potentially eligible for endovascular thrombectomy: A population-based study, Stroke J. Cereb. Circ, vol.47, pp.1377-1380, 2016. ,
Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: Real-world experience and a call for action, Stroke J. Cereb. Circ, vol.41, p.5, 2010. ,
Early recanalization after intravenous administration of recombinant tissue plasminogen activator as assessed by pre-and post-thrombolytic angiography in acute ischemic stroke patients, Stroke J. Cereb. Circ, vol.38, pp.192-193, 2007. ,
Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke, N. Engl. J. Med, vol.372, pp.2285-2295, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-02007226
Estimating the number of UK stroke patients eligible for endovascular thrombectomy, Eur. Stroke J, vol.2, p.3, 2017. ,
Eligibility for mechanical thrombectomy in acute ischemic stroke: A phase IV multi-center screening log registry, J. Neurol. Sci, vol.371, pp.96-99, 2016. ,
Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: The Multicenter rt-PA Stroke Survey, Circulation, vol.105, pp.1679-1685, 2002. ,
Tissue plasminogen activator for acute ischemic stroke, N Engl J Med, vol.333, pp.14333-2401, 1995. ,
1,026 experimental treatments in acute stroke, Ann. Neurol, vol.59, pp.467-477, 2006. ,
Heart disease and stroke statistics-2018 update: A report from the, American Heart Association. Circulation, vol.137, pp.67-492, 2018. ,
The two pathophysiologies of focal brain ischemia: Implications for translational stroke research, J. Cereb. Blood Flow Metab, vol.32, p.186, 2012. ,
A reproducible model of thromboembolic stroke in mice, NeuroReport, vol.9, pp.2967-2970, 1998. ,
, Scientific RepoRtS |, vol.10, p.12191, 2020.
A new rat model of thrombotic focal cerebral ischemia, J. Cereb. Blood Flow Metab, vol.17, pp.123-135, 1997. ,
Effects of microplasmin on recovery in a rat embolic stroke model, Neurol. Res, vol.30, pp.75-81, 2008. ,
, Rodent Models of Stroke, pp.55-70, 2010.
Preclinical stroke research-advantages and disadvantages of the most common rodent models of focal ischaemia, Br. J. Pharmacol, vol.164, pp.1062-1078, 2011. ,
Cerebral infarction in rats using homologous blood emboli: Development of a new experimental model, Stroke J. Cereb. Circ, vol.16, pp.76-84, 1985. ,
An animal model of cerebral infarction. Homologous blood clot emboli in rats, Stroke J. Cereb. Circ, vol.13, pp.505-508, 1982. ,
Patency of cerebral microvessels after focal embolic stroke in the rat, J. Cereb. Blood Flow Metab, vol.21, pp.413-421, 2001. ,
Mouse model of in situ thromboembolic stroke and reperfusion, Stroke J. Cereb. Circ, vol.38, p.0, 2007. ,
Efficacy of alteplase in a mouse model of acute ischemic stroke: A retrospective pooled analysis, Stroke J. Cereb. Circ, vol.47, pp.1312-1318, 2016. ,
Fingolimod reduces hemorrhagic transformation associated with delayed tissue plasminogen activator treatment in a mouse thromboembolic model, Stroke J. Cereb. Circ, vol.44, p.3, 2013. ,
A mouse model of hemorrhagic transformation by delayed tissue plasminogen activator administration after in situ thromboembolic stroke, Stroke J. Cereb. Circ, vol.42, pp.196-203, 2011. ,
Thromboembolic stroke in C57BL/6 mice monitored by 9.4 T MRI using a 1H cryo probe, Exp. Transl. Stroke Med, vol.4, 2012. ,
Long-term behavioral assessment of function in an experimental model for ischemic stroke, J. Neurosci. Methods, vol.196, pp.247-257, 2011. ,
The stairway: A novel behavioral test detecting sensomotoric stroke deficits in rats, Artif. Organs, vol.30, pp.756-763, 2006. ,
Rat models of upper extremity impairment in stroke, ILAR J, vol.48, pp.374-384, 2007. ,
Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke, Ann. Neurol, vol.32, pp.78-86, 1992. ,
Molecular mechanisms of thrombin function, Cell Mol. Life Sci, vol.53, pp.701-730, 1997. ,
Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke, Stroke J. Cereb. Circ, vol.38, pp.948-954, 2007. ,
Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies, Drug Discov. Today, vol.17, p.11, 2012. ,
Acute ischemic stroke: Overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia, Pharmacol. Biochem. Behav, vol.87, pp.179-197, 2007. ,
d-Amphetamine improves cognitive deficits and physical therapy promotes fine motor rehabilitation in a rat embolic stroke model, Acta Neurol. Scand, vol.113, pp.189-198, 2006. ,
The site of embolization related to infarct size, oedema and clinical outcome in a rat stroke model-further translational stroke research, Exp. Transl. Stroke Med, vol.2, 2010. ,
Immune responses and anti-inflammatory strategies in a clinically relevant model of thromboembolic ischemic stroke with reperfusion, Transl. Stroke Res, 2019. ,
Assessment of clinical outcomes in acute stroke trials, Stroke J. Cereb. Circ, vol.29, pp.986-991, 1998. ,
& Canadian Alteplase for Stroke Effectiveness Study, I. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study, CMAJ, vol.172, pp.1307-1312, 2005. ,
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke, N. Engl. J. Med, vol.359, pp.1317-1329, 2008. ,
Reperfusion within 6 hours outperforms recanalization in predicting penumbra salvage, lesion growth, final infarct, and clinical outcome, Stroke J. Cereb. Circ, vol.46, pp.1582-1589, 2015. ,
Association of survival and hyperthermia after rt-PA for ischemic stroke, Acta Neurol. Scand, vol.138, pp.574-578, 2018. ,
Hyperthermia masks the neuroprotective effects of tissue plaminogen activator, Stroke J. Cereb. Circ, vol.36, pp.665-669, 2005. ,
Toll-like receptor 4 mediates hemorrhagic transformation after delayed tissue plasminogen activator administration in in situ thromboembolic stroke, Stroke J. Cereb. Circ, vol.48, p.6, 2017. ,
Delayed rt-PA treatment in a rat embolic stroke model: Diagnosis and prognosis of ischemic injury and hemorrhagic transformation with magnetic resonance imaging, J. Cereb. Blood Flow Metab, vol.21, pp.964-971, 2001. ,
The rtPA (alteplase) 0-to 6-hour acute stroke trial, part A (A0276g): Results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators, Stroke J. Cereb. Circ, vol.31, pp.811-816, 2000. ,
Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct, N. Engl. J. Med, vol.378, pp.11-21, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02387070
Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro, Thromb. Haemost, vol.46, pp.561-565, 1981. ,
Tissue Plasminogen Activator for preclinical stroke research: Neither "rat" nor "human" dose mimics clinical recanalization in a carotid occlusion model, Sci. Rep, vol.5, 2015. ,
Human recombinant tissue-plasminogen activator (alteplase): Why not use the "human" dose for stroke studies in rats, J. Cereb. Blood Flow Metab, vol.30, p.33, 2010. ,
, Scientific RepoRtS |, vol.10, p.12191, 2020.
, Franke and Margareta Bergqvist Foundation, Knut and Alice Wallenberg Foundation, Olle Engqvist Foundation, Thure Carlsson Foundation, com/scientificreports/ (Experimental Vascular Research) for the use of their facilities. This work was supported by the Swedish Heart-Lung Foundation, pp.2019-0308, 20170883.